Eli Lilly working on a heart drug that may benefit Indians: CEO David Ricks

Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, potentially reducing it by 85%-90%. With heart disease cases surging in India, this phase 3 trial drug promises significant cardiovascular benefits, requiring only once-a-year administration. It's crucial, given the rising heart ailments in the region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nVcmHpP
via IFTTT